January 11, 2023
Via: Biopharma DiveAirsupra is part of a growing portfolio of new drugs that are helping offset wilting sales of older AstraZeneca respiratory medicines such as Pulmicort. It’s an essential therapeutic area for the British drugmaker; in the third quarter, respiratory and immunology […]
Clinical Trials, FDA, Regulations, Research and Development
November 9, 2022
Via: PharmaphorumPT027 is based on beta agonist albuterol and corticosteroid budesonide – two well-established therapies – combined into a fixed-dose inhaler that can be used as rescue medication when a patient with asthma is in the throes of an attack. The […]
Clinical Trials, Research and Development
September 28, 2022
Via: Drugs.comAluminum in childhood vaccines has long been the cause of speculation about a potential link to allergies and asthma, but a new study designed to figure out whether there might be a connection did not come to a definitive conclusion. […]
Clinical Trials, Research and Development
September 7, 2021
Via: FierceBiotechPiece by piece, Amgen and AstraZeneca are building the case for their potential asthma blockbuster. The latest brick to fall into place comes from a new slice of phase 3 data, which suggests tezepelumab may be particularly effective in a […]
March 4, 2021
Via: BioSpaceRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on treatment for children aged 6 to 11 […]
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
August 30, 2023
September 19, 2023
Copyright © 2023. All rights reserved
